Reviews/Polyphenols and Antioxidants/Vitamin C and common cold
Sup · POLY-SUP-03 · v2
Borderline: within 4 points of the Doubtful/Refuted boundary, so a re-grade could land either side.
This corpus asks whether taking vitamin C stops people catching colds, and the eligible trials mostly point against a blanket 'it does nothing' claim. Four of the five relevant randomised trials found fewer colds in the vitamin C groups [1][3][4][5], but those positive results come mainly from unusual groups: villagers with a stomach condition [1], men whose vitamin C levels were already low [3], and army recruits under the physical strain of training [4]. The one large trial in ordinary adult women [2] found no effect on everyday ('simple') colds at all. So the evidence suggests vitamin C may reduce colds in some stressed or deficient groups, while leaving open that it does little for the general population. The panel therefore treated the sweeping 'does not prevent' wording as probably wrong, yet not cleanly disproven, because the strongest counter-evidence does not come from ordinary people.
Four of five eligible randomised trials report fewer colds with vitamin C: a high-dose arm showed a relative risk of 0.34 (0.12-0.97) for suffering three or more colds in atrophic-gastritis villagers [1], cold incidence fell with RR 0.55 (95% CI 0.33-0.94; p = 0.04) in men with marginal vitamin C status [3], 1444 Korean Army recruits on 6000 mg/day had a 0.80-fold lower risk of a cold [4], and a 168-volunteer study recorded significantly fewer colds (37 vs 50, P<.05) [5]. Against this, the largest general-population trial, 688 adult women on 1 g/day, found a small reduction in chest colds but 'no evidence of any effect on simple colds' [2]. The positive signals concentrate in deficiency-prone or physically stressed groups [1][3][4], while the one ordinary-population trial is null on everyday colds [2]. The corpus thus demonstrates population-dependent prevention rather than a uniform effect either way. The contested point: The division is between populations, not direction of effect: vitamin C appears to reduce colds in deficient or physically stressed groups [1][3][4], while the largest trial of ordinary adults [2] finds no effect on simple colds. Whether the claim is 'false' therefore depends entirely on whether it is read as a universal statement or as a statement about the general population.
All 16 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Polyphenols and Antioxidants, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The strongest prevention signals come from special populations — atrophic-gastritis villagers [1], men with marginal vitamin C status [3], and military recruits under training stress [4]. Prevention in deficiency-prone or stressed groups does not establish prevention in the general population, which is what the blanket claim addresses.
[1] is a 50 vs 500 mg dose comparison with no placebo and an explicit author warning that 'the findings should be interpreted with caution' due to protocol amendment; its effect is confined to a recurrent-cold subgroup with no effect on severity or duration.
Where it remains uncertain. The prevention signals come from special populations [1][3][4], while the largest general-population trial reports 'no evidence of any effect on simple colds' [2].
Aleatory
The marginal-status trial rests on n = 15 vs n = 13 [3] and the diary study on 168 volunteers [5], so random variation can swing the observed cold counts materially.
Epistemic
The eligible set lacks a large, placebo-controlled, general-population incidence trial, so whether vitamin C prevents colds in ordinary people is simply not measured head-on [2][3][4].
Inferential
Extending prevention seen in atrophic-gastritis villagers [1], marginal-status men [3], and training recruits [4] to the general population is an inferential leap the corpus does not license.
The load-bearing papers from a corpus of 16, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Largest general-population trial: null on ordinary colds, which partially supports the claim and tempers the refutation.
“There is evidence of a small reduction by vitamin C in the mean number of chest colds, but no evidence of any effect on simple colds.”
Panel auditInternal validity: medium · scope of inference: Adult women in a community setting taking 1 g/day.Key limitations: no quantitative results in abstract · subgroup fishing explored then rejected
High-dose vitamin C cut the frequency of recurrent (≥3) colds versus low dose, contradicting 'does not prevent'; but no placebo arm and no effect on severity/duration.
“the relative risks (95% confidence interval (CI)) of suffering from a common cold three or more times during the survey period was 0.34 (0.12-0.97) for the high-dose group. No apparent reduction was seen for the severity and duration of the common cold.”
Panel auditInternal validity: low · scope of inference: Older Japanese villagers with atrophic gastritis in a high gastric-cancer region, comparing two active doses.Key limitations: no placebo arm · protocol amendment · special population · high dropout
2 of 16 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus leans against the claim but shows population-dependent prevention rather than a clean general-population refutation, placing confidence in the claim low but above the Refuted threshold.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Large general-population placebo-controlled incidence trial. The eligible set has no adequately powered placebo-controlled trial of cold incidence in an unselected general population, which is exactly what the blanket claim addresses; [2] is the closest but is limited to women and null on simple colds. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large double-blind placebo-controlled RCT in unselected adults across the cold season, pre-registering cold incidence as the primary outcome with objective or validated symptom ascertainment.
Open question: Does vitamin C supplementation prevent common colds in an unselected general population, as opposed to in deficient or physically stressed groups? Why it is still open: The positive trials are in special populations [1][3][4] and the one large general-population trial [2] found no effect on simple colds, so the general-population case is not settled.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19